Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
- PMID: 32984493
- PMCID: PMC7498849
- DOI: 10.1016/j.gore.2020.100631
Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
Abstract
Vulvar cancer remains a rare entity and treatment options for advanced disease are limited. This case report highlights the excellent response of two patients with FIGO Stage IV vulvar cancer treated with neoadjuvant paclitaxel/carboplatin/bevacizumab chemotherapy. While definitive conclusions are impossible, neoadjuvant chemotherapy may ultimately prove to be a better initial treatment option for locally advanced disease in terms of quality of life and response compared to the traditional chemoradiation regimens.
Keywords: Advanced vulvar cancer; Bevacizumab; Carboplatin; Neoadjuvant therapy; Paclitaxel.
© 2020 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures







Similar articles
-
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?Cancers (Basel). 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. Cancers (Basel). 2021. PMID: 34439215 Free PMC article. Review.
-
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5. Clin Breast Cancer. 2011. PMID: 21729666 Clinical Trial.
-
Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer.Gynecol Obstet Invest. 2018;83(6):620-626. doi: 10.1159/000487435. Epub 2018 Sep 18. Gynecol Obstet Invest. 2018. PMID: 30227411
-
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox015. Dis Esophagus. 2017. PMID: 28475724
-
Systemic treatment of vulvar cancer.Expert Rev Anticancer Ther. 2015 Jun;15(6):629-37. doi: 10.1586/14737140.2015.1037837. Epub 2015 May 21. Expert Rev Anticancer Ther. 2015. PMID: 25997120 Review.
Cited by
-
Management of Advanced Squamous Cell Carcinoma of the Vulva.Cancers (Basel). 2021 Dec 30;14(1):167. doi: 10.3390/cancers14010167. Cancers (Basel). 2021. PMID: 35008331 Free PMC article. Review.
-
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?Cancers (Basel). 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061. Cancers (Basel). 2021. PMID: 34439215 Free PMC article. Review.
-
Advances in Vulvar Cancer: A Radiation Oncology Perspective.Cancers (Basel). 2025 Jul 22;17(15):2415. doi: 10.3390/cancers17152415. Cancers (Basel). 2025. PMID: 40805118 Free PMC article. Review.
References
-
- Gray H.J. Advances in vulvar and vaginal cancer treatment. Gynecol. Oncol. 2010;118:3–5. - PubMed
-
- Horowitz N.S. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol. Oncol. 2012;127:141–146. - PubMed
-
- MacLean A.B. Role of angiogenesis in benign, premalignant and malignant vulvar lesions. J. Reprod. Med. 2000;45:609–612. - PubMed
-
- Moore D.H. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol. Oncol. 2012;124:529–533. - PubMed
-
- National Comprehensive Cancer Network. Vulvar Cancer (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf (accessed May 8, 2020).
Publication types
LinkOut - more resources
Full Text Sources